Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6779534 | 0.88 | MAOB (0.65) | MAPTRAB9AMAOBNR4A1NR4A2 | |
| SCHEMBL25686475 | 0.85 | MAPT (0.75) | MAPTRAB9AMAOBNR4A1NR4A2 | |
| SCHEMBL23754729 | 0.84 | MAPT (0.62) | MAPTRAB9AADRB2ADRB1ADRB3 | |
| SCHEMBL1595091 | 0.83 | L3MBTL1 (0.46) | MAPTMAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL2984321 | 0.82 | MAOB (0.74) | MAPTRAB9AMAOBNR4A1NR4A2 | |
| SCHEMBL24047115 | 0.82 | NR4A2 (0.73) | RAB9AMAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL17921575 | 0.82 | MAOB (0.50) | MAPTRAB9AMAOBNR4A1NR4A2 | |
| SCHEMBL4839180 | 0.81 | MAPT (0.71) | MAPTRAB9AADRB2ADRB1ADRB3 | |
| SCHEMBL30244536 | 0.81 | MAPT (0.53) | MAPTRAB9APKML3MBTL1 | |
| SCHEMBL7270321 | 0.81 | MAPT (0.53) | MAPTRAB9APKML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418203-B1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO CO LTD (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-8410273-B2 | Cyclic compound having substituted phenyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| EP-2565185-A1 | [5,6]HETEROCYCLIC COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20130029964-A1 | [5, 6] HETEROCYCLIC COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-31 | — | — | US | disclosed |
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-2418203-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | Daiichi Sankyo Company, Limited (JP) | 2012-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | BMP2, BMP4, BMP6 | MAPT 4571/4885RAB9A 805/4885MAOB 4264/4885 |
| US-20130029964-A1 | [5, 6] HETEROCYCLIC COMPOUND | BMP2, BMP4, SOST | MAPT 4842/4885RAB9A 2636/4885MAOB 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.